Opinion
Video
Author(s):
Focusing on castration-resistant prostate cancer, the panel reviews treatment options for patients with metastatic and nonmetastatic disease.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer
Dr. Murphy on increasing diversity in cancer clinical trials
Prostate cancer awareness in 2025: A human imperative in the wake of President Biden’s diagnosis
GLP-1 agonist use is rising in men with prostate cancer
Ultrasound imaging system now available to guide nonsurgical urology procedures
CPT 49186 vs 38780: Coding retroperitoneal mass excision
From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance